Publications
Number
Publication
Language
Pharma Location Switzerland
MFN: Looking forward
MFN is already affecting Switzerland: companies are delaying or pausing launches. Low Swiss prices remain a strategic vulnerability beyond 2029, so Switzerland should prepare now.
MFN: Looking forward
Health Panorama 2026/2027
Key facts and figures on the Swiss health and pharmaceutical landscape: Health Panorama assesses the current developments, provides relevant data and background information and offers food for thought for the political debate.
Health Panorama 2026/2027
Research and Development
Switzerland as a research hub
Medical innovations do not occur in isolation; they require a strong ecosystem made up of universities, hospitals, researchers and industry.